Biocon and Viatris have enjoyed a long and mutually beneficial partnership since 2009. Together, we invested ahead of time in R&D, manufacturing scale and capability building, for biosimilars. Together, we achieved many global ‘firsts’ and set new benchmarks for the global biosimilars industry.

The historic transaction between Biocon Biologics and Viatris will create a uniquely positioned, vertically integrated organization that aspires to be a global biosimilars leader. As a global company with singular focus on biosimilars, we are well placed to achieve this ambition.

Our 40-year legacy of being on the cutting edge of science and technology has enabled us to build a cost competitive, global scale enterprise encompassing a unique portfolio of 20 biosimilar assets, including insulins and monoclonal antibodies spanning therapy areas such as diabetes, oncology, immunology and ophthalmology.

With the closing of the deal, Biocon Biologics has full ownership of its collaboration assets, bTrastuzumab, bPegfilgrastim, bBevacizumab, bGlargine, bAspart, bPertuzumab and bGlargine 300U as well as Viatris’ rights for the in-licensed immunology products of bAdalimumab and bEtanercept. Biocon Biologics has also acquired Viatris’ rights for bAflibercept, which is used to treat several ophthalmology conditions. Viatris has been the ‘first to file’ bAflibercept in the U.S.

We also have significant global scale manufacturing capacity dedicated to biosimilars.

Integrating our talent, development, manufacturing and commercial expertise, will lead to seamless operations and customer service, enabling us to deliver on our promise of providing affordable access to essential and lifesaving biosimilars to patients across the globe.

By building deeper capabilities, robust supply chains and stronger leadership, we can create a technology-enabled, future-ready biosimilars organization that projects a strong globally recognized brand.

• Biocon Biologics has established its scientific credibility, global-scale manufacturing prowess and quality expertise through commercialization of its 8 biosimilar products across geographies through its direct presence and partnership model.
• Biocon Biologics’ businesses is built on patient centricity, ethics and business integrity.
• Biocon Biologics offers a unique global value proposition through its comprehensive biosimilars portfolio spanning both insulins and monoclonal antibodies.
• Comprehensive biosimilars portfolio of 20 products spanning both insulins and monoclonal antibodies across therapy areas such as Diabetes, Oncology and Inflammatory Diseases.
• Biocon Biologics is developing a strong portfolio of biosimilars that will address a USD 70 billion global market opportunity by FY27.
• Significant global scale manufacturing capacity dedicated to biosimilars.